✦ LIBER ✦

Serotonin precursor effects in tardive dyskinesia

✍ Scribed by Henry A. Nasrallah; Robert E. Smith; Frederick J. Dunner; Mona McCalley-Whitters

Publisher: Springer
Year: 1982
Tongue: English
Weight: 208 KB
Volume: 77
Category: Article
ISSN: 0033-3158
DOI: 10.1007/bf00464572

No coin nor oath required. For personal study only.

✦ Synopsis

In an attempt to determine the role of serotoninergic mechanisms in the pathophysiology of tardive dyskinesia, the serotonin precursor 5-hydroxytryptophan (5 HTP) with carbidopa, a peripheral decarboxylase inhibitor, were given in a double-blind crossover design to seven patients with longstanding tardive dyskinesia. In the five patients who completed the study, there was no change in dyskinetic movements. Most of the patients had worsening of psychotic symptoms with 5HTP. The data suggest that serotonin precursors have no therapeutic effects in tardive dyskinesia. The implications for the role of serotonin in the pathophysiology of tardive dyskinesia are discussed.

📜 SIMILAR VOLUMES

Bereitschaftspotential in tardive dyskin

Bereitschaftspotential in tardive dyskinesia

✍ Dr. Lawrence E. Adler; Mark Pecevich; Herbert Nagamoto 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 518 KB

The bereitschaftspotential or motor readiness potential is a slow negative electroencephalographic wave occurring 150-1500 ms prior to the onset of a voluntary movement. It was measured in 33 subjects: 11 normal controls, 11 medicated schizophrenics with no tardive dyskinesia or evidence of drug-ind

Clozapine in tardive dyskinesia

✍ George M. Simpson; J. Hillary Lee; Ram K. Shrivastava 📂 Article 📅 1978 🏛 Springer 🌐 English ⚖ 468 KB

Naloxone in tardive dyskinesia

✍ I. Blum; P. F. Nisipeanu; E. Roberts 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 90 KB

Sulpiride in tardive dyskinesia

✍ Daniel E. Casey; Jes Gerlach; Hans Simmelsgaard 📂 Article 📅 1979 🏛 Springer 🌐 English ⚖ 407 KB

Tardive dyskinesia can be suppressed by drugs that block dopaminergic receptors, but often at the cost of a concomitant increase in parkinsonism. Sulpiride (400 -- 2100 mg/day), a selective type-2 dopamine receptor antagonist, was evaluated in a blind, placebo-controlled trial in 11 patients with ta

Effect of baclofen on tardive dyskinesia

✍ J. Gerlach; T. Rye; P. Kristjansen 📂 Article 📅 1978 🏛 Springer 🌐 English ⚖ 588 KB

Butaperazine pharmacokinetics in tardive

Butaperazine pharmacokinetics in tardive dyskinesia

✍ Dr. Marion E. Wolf; Javaid I. Javaid; Aron D. Mosnaim; John M. Davis 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB

failed to show any significant differences in the steady-state serum levels of thioridazine or its metabolites between TD and non-TD schizophrenic subjects.